

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7314061

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NUCHEM THERAPEUTICS INC.	05/17/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VIGIL NEUROSCIENCE, INC.
<b>Street Address:</b>	ONE BROADWAY SUITE 07-300
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17302502
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)275-8374
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6177287100
<b>Email:</b>	BOSpatents@dechert.com
<b>Correspondent Name:</b>	DECHERT LLP
<b>Address Line 1:</b>	ONE INTERNATIONAL PLACE, 40TH FLOOR
<b>Address Line 2:</b>	100 OLIVER STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	403433-005US (183057)
<b>NAME OF SUBMITTER:</b>	ANDREA L.C. REID
<b>SIGNATURE:</b>	/Andrea L.C. Reid/
<b>DATE SIGNED:</b>	05/04/2022
<b>Total Attachments: 2</b>	
source=403433-005US 183057 Assignment 4 Nuchem to Vigil#page1.tif	
source=403433-005US 183057 Assignment 4 Nuchem to Vigil#page2.tif	

## CONFIRMATION OF ASSIGNMENT

WHEREAS, we, the undersigned, **NUCHEM THERAPEUTICS INC.**, having a place of business at **2350 Cohen Street, Suite 201, Saint-Laurent, Quebec, H4R 2N6, CANADA** (hereinafter termed "Assignor"), owner of an interest in the right, title and interest in and to certain new and useful improvements disclosed in **HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**, for which an application for a patent of the United States, having Application No. 17/302,502 was filed May 4, 2021, by virtue of a prior assignment from inventors Maxence BOS, John MANCUSO, and Ivan FRANZONI (hereinafter termed "Inventors"), and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries;

WHEREAS, **VIGIL NEUROSCIENCE, INC.**, having a place of business at **300 Technology Square, 8<sup>th</sup> Floor, Cambridge, Massachusetts 02139, USA** (hereinafter termed "Assignee"), is desirous of acquiring Assignor's entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:


1. Said Assignor does hereby sell, assign, transfer and convey, and/or confirm prior sale, assignments, transfer, and conveyance, unto said Assignee, Assignor's entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefore and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.

4. Said Assignor hereby warrants and represents that he has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignor.

	Assignor:	NUCHEM THERAPEUTICS INC.
Date: <u>MAY 17/2021</u>	Signed:	
	Print Name:	<u>JOHN MANCUSO</u>
	Print Title:	<u>PARTNER</u>
	Address:	2350 Cohen Street, Suite 201 Saint-Laurent, Quebec H4R 2N6 CANADA

Date: May 23, 2021

Assignee: VIGIL NEUROSCIENCE, INC.

Signed: 

Print Name: Ivana Magovcevic-Liebisch

Print Title: President & CEO

Address: 300 Technology Square, 8<sup>th</sup> Floor  
Cambridge, Massachusetts 02139  
USA